Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Overview of a promising new study of venetoclax in patients with CLL

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.